In a June 10 story about diabetes treatment research, The Associated Press reported erroneously that LY2605541 is a short-acting insulin. It is a long-acting insulin.
Also, Johnson & Johnson applied for U.S. approval to sell its experimental diabetes pill canagliflozin on May 31, not May 29.
Did Rubio deal a mortal blow to ObamaCare?
- How ‘Gross Output’ Predicted the Economy’s Slowdown
Donald Trump Mocks A Disabled New York Times Reporter | RedState
Ann Coulter - Importing Terrorism and Other American Values
'POTUS is trolling #Thanksgiving': In weekly address, Obama likens Syrian refugees to Mayflower pilgrims
Importing Terrorism and Other American Values | Human Events
Top 5 "Go To" Rifle Essentials - Bearing Arms - Video